These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8136818)

  • 1. Hydroxychloroquine, dosage parameters and retinopathy.
    Spalton DJ; Verdon Roe GM; Hughes GR
    Lupus; 1993 Dec; 2(6):355-8. PubMed ID: 8136818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
    Rüther K; Foerster J; Berndt S; Schroeter J
    Ophthalmologe; 2007 Oct; 104(10):875-9. PubMed ID: 17653725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
    Michaelides M; Stover NB; Francis PJ; Weleber RG
    Arch Ophthalmol; 2011 Jan; 129(1):30-9. PubMed ID: 21220626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice.
    Browning DJ
    Am J Ophthalmol; 2013 Mar; 155(3):418-428.e1. PubMed ID: 23218706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
    Mititelu M; Wong BJ; Brenner M; Bryar PJ; Jampol LM; Fawzi AA
    JAMA Ophthalmol; 2013 Sep; 131(9):1187-97. PubMed ID: 23887202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.
    Lai TY; Ngai JW; Chan WM; Lam DS
    Doc Ophthalmol; 2006 May; 112(3):177-87. PubMed ID: 16804707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography.
    Lyons JS; Severns ML
    Am J Ophthalmol; 2007 May; 143(5):801-809. PubMed ID: 17336914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early paracentral visual field loss in patients taking hydroxychloroquine.
    Elder M; Rahman AM; McLay J
    Arch Ophthalmol; 2006 Dec; 124(12):1729-33. PubMed ID: 17159032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal toxicity in long term hydroxychloroquine treatment.
    Mavrikakis M; Papazoglou S; Sfikakis PP; Vaiopoulos G; Rougas K
    Ann Rheum Dis; 1996 Mar; 55(3):187-9. PubMed ID: 8712882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.
    Maturi RK; Yu M; Weleber RG
    Arch Ophthalmol; 2004 Jul; 122(7):973-81. PubMed ID: 15249360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness.
    Agarwal P; Wong YH; Dasgupta E; Agarwal R; Livingstone BI; Ramamurthy S; Chyn GS
    Cutan Ocul Toxicol; 2015; 34(3):179-84. PubMed ID: 25068998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography.
    So SC; Hedges TR; Schuman JS; Quireza ML
    Ophthalmic Surg Lasers Imaging; 2003; 34(3):251-8. PubMed ID: 12757106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of screening procedures in hydroxychloroquine toxicity.
    Marmor MF
    Arch Ophthalmol; 2012 Apr; 130(4):461-9. PubMed ID: 22159170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy.
    Rodriguez-Padilla JA; Hedges TR; Monson B; Srinivasan V; Wojtkowski M; Reichel E; Duker JS; Schuman JS; Fujimoto JG
    Arch Ophthalmol; 2007 Jun; 125(6):775-80. PubMed ID: 17562988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
    Leung LS; Neal JW; Wakelee HA; Sequist LV; Marmor MF
    Am J Ophthalmol; 2015 Oct; 160(4):799-805.e1. PubMed ID: 26189086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine therapy in massive total doses without retinal toxicity.
    Johnson MW; Vine AK
    Am J Ophthalmol; 1987 Aug; 104(2):139-44. PubMed ID: 3618711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinopathy and antimalarial drugs--the British experience.
    Spalton DJ
    Lupus; 1996 Jun; 5 Suppl 1():S70-2. PubMed ID: 8803916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term course of chloroquine retinopathy after cessation of medication.
    Brinkley JR; Dubois EL; Ryan SJ
    Am J Ophthalmol; 1979 Jul; 88(1):1-11. PubMed ID: 463998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Static perimetry in chloroquine retinopathy. Perifoveal patterns of visual field depression.
    Hart WM; Burde RM; Johnston GP; Drews RC
    Arch Ophthalmol; 1984 Mar; 102(3):377-80. PubMed ID: 6703984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Supervision of the eyes during prolonged treatment with synthetic antimalarial drugs. Results in 237 patients followed up for 4 years on the average].
    Bertrand JJ; Debeyre N; Kahn MF; Ryckewaert A
    Presse Med (1893); 1968 Nov; 76(45):2139-42. PubMed ID: 5720115
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.